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Background: Type II focal cortical dysplasias (FCDs) are malformations of cortical development characterised by the
disorganisation of the normal neocortical structure and the presence of dysmorphic neurons (DNs) and balloon
cells (BCs). The pathogenesis of FCDs has not yet been clearly established, although a number of histopathological
patterns and molecular findings suggest that they may be due to abnormal neuronal and glial proliferation and
migration processes.
In order to gain further insights into cortical layering disruption and investigate the origin of DNs and BCs, we used
in situ RNA hybridisation of human surgical specimens with a neuropathologically definite diagnosis of Type IIa/b
FCD and a panel of layer-specific genes (LSGs) whose expression covers all cortical layers. We also used anti-phospho-S6
ribosomal protein antibody to investigate mTOR pathway hyperactivation.
Results: LSGs were expressed in both normal and abnormal cells (BCs and DNs) but their distribution was different.
Normal-looking neurons, which were visibly reduced in the core of the lesion, were apparently located in the
appropriate cortical laminae thus indicating a partial laminar organisation. On the contrary, DNs and BCs, labelled
with anti-phospho-S6 ribosomal protein antibody, were spread throughout the cortex without any apparent rule
and showed a highly variable LSG expression pattern. Moreover, LSGs did not reveal any differences between Type
IIa and IIb FCD.
Conclusion: These findings suggest the existence of hidden cortical lamination involving normal-looking neurons,
which retain their ability to migrate correctly in the cortex, unlike DNs which, in addition to their morphological
abnormalities and mTOR hyperactivation, show an altered migratory pattern.
Taken together these data suggest that an external or environmental hit affecting selected precursor cells during
the very early stages of cortical development may disrupt normal cortical development.
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Focal cortical dysplasias (FCDs) are malformations of
cortical development that are frequently associated with
intractable epilepsy and are characterised by cortical
dyslamination and abnormal cell morphology [1]. The
most recent classification [2] recognises three types of
FCD, with Type II being divided into two subtypes on
the basis of the presence of dysmorphic neurons (DNs)
alone (type IIa) or DNs together with balloon cells (BCs;
Type IIb).
In both cases, cortical architecture is profoundly al-
tered particularly within the core of the lesion, where
DNs and normal-sized pyramidal cells co-exist with an
overall reduction in neuronal density [3,4]. In addition
to morphological changes (cytomegaly, abnormal den-
dritic arbors, and the loss of radial orientation), DNs are
characterised by the aberrant expression of neuronal and
glial markers with a prevalently neuronal-mature identity.
BCs are also characterised by morphological anomalies
such as voluminous cytoplasms, displaced nuclei and the
co-expression of different mature/immature neuronal/glial
markers with a prevalently glial-immature phenotype
[5-7]. The lack of a clear cell-type specification may reflect
alterations in normal neuronal and glial proliferation [2,8]
and subsequent migration.
The cytological similarities between Type II FCD and
tuberous sclerosis complex (TSC), a genetic disorder due
to mutations in the TSC1 or TSC2 gene, and evidence of
abnormal activation of the mammalian target of rapamy-
cin (mTOR) signalling cascade, have led to the hypothesis
that this pathway is involved in the pathogenesis of DNs
and BCs [7,9,10], the origin of which is still debated. It
has been suggested that they may arise from radial glial
progenitor cells in the Ventricular Zone (VZ) [11], but it
is still unclear whether they derived from a single or
multiple progenitor cell, or whether they arise at a particu-
lar moment or at different times during the proliferation
phase [12].
One means of gaining further insights into the struc-
tural abnormalities of dysplastic cortex and clarifying
the cellular origin of DNs and BCs is to evaluate the ex-
pression patterns of an appropriate panel of layer-
specific genes (LSGs). Despite their specific functions
such as transcription factors, calcium-binding proteins,
receptors, etc.), these genes have the distinctive charac-
teristic of being expressed in (mainly glutamatergic)
cortical neurons with very high laminar specificity, and
can thus be used as markers to identify different cor-
tical layers. This not only allows specific neuronal sub-
populations to be identified on the basis of their
expression profiles, but also provides information con-
cerning their birth dates and migration [13,14]. Over
the last few years, a number of studies have used LSGs
to investigate cortical development under normal andpathological conditions in animal models [15-18] and
humans [19-25].
The aim of this study was to investigate the expression
of a panel of LSGs covering all cortical layers (Cux2,
Rorβ, Er81, Nurr1 and CTGF) in surgical specimens
from a cohort of 20 patients with a neuropathological
diagnosis of Type IIa/b FCD in order to learn more
about cortical layering disruption and the origin of DNs
and BCs.
Methods
Patient and specimen selection
We collected specimens from 20 patients who underwent
surgery to treat intractable epilepsy at the C. Munari Epi-
lepsy Surgery Centre of Niguarda Hospital and the De-
partment of Neurosurgery of Besta Neurological Institute
(both in Milan, Italy). The protocols of the pre-surgical
investigation procedures were the same at both centres,
and included high-resolution magnetic resonance imaging
(MRI) and video-electroencephalography (VEEG) moni-
toring in order to define the epileptogenic zone and surgi-
cal strategy. The following individual MRI aspects were
considered: focal thickening of the cortex, blurring of the
grey/white matter junction, abnormal signal intensity in
the cortex and subcortical white matter, tapering of white
matter signal changes towards the ventricle (trasmantle
sign). The C. Munari Centre also used invasive pre-
surgical procedures (i.e. stereo-EEG) after appropriate
discussions when the imaging and non-invasive electro-
clinical data were discordant.
All of the resections were performed for strictly thera-
peutic reasons after informed consent had been obtained.
The pre-surgical procedures for selecting candidates
for epilepsy surgery have been described in detail else-
where [26].
All of the patients had a neuropathological diagnosis
of Type II FCD. The cortical specimens were divided into
two groups: Type IIa (8 cases) and Type IIb (12 cases).
Table 1 summarises the patients’ main clinical features.
Immunohistochemical procedures
After surgical resection, the specimens were fixed in 4%
paraformaldehyde for 24–36 hours, and alternate 5 mm
thick slabs were embedded in paraffin for routine
neuropathology or cut into 50 μm thick serial sections
by means of a vibratome (VT1000S, Leica, Heidelberg,
Germany) and addressed for the present study. For the
routine neuropathological investigations, 7 μm thick
sections were stained with hematoxylin and eosin, thio-
nin, Kluver-Barrera and Bielschowsky stains, and add-
itional series were processed for immunohistochemistry
(IHC). The vibratome sections were also stained with
thionin and processed for IHC. The following primary
antibodies were used: monoclonal antibodies against
Table 1 Clinical and neuropathological findings












1 0 1 300 L/TO FCD IIa Ia
2 10 29 30 L/T FCD IIa IV
3 0 2 100 L/O FCD IIa Ia
4 0 13 60 L/O FCD IIa Ia
5 0 1 60 R/F FCD IIa Ia
6 1 9 600 R/FCP FCD IIa Ia
7 4 29 2 L/T FCD IIa Ia
8 0 31 60 L/TO FCD IIa Ic
9 0 25 30 R/TPO FCD IIb Ia
10 3 39 30 R/T FCD IIb Ia
11 2 4 300 L/P FCD IIb Ia
12 2 45 20 R/F FCD IIb Id
13 2 3 10 L/F FCD IIb IIb
14 4 22 40 L/T FCD IIb Ia
15 8 47 45 R/F FCD IIb III
16 10 14 100 R/F FCD IIb II
17 8 11 20 L/T FCD IIb Ia
18 0 13 1 R/F FCD IIb Ia
19 1 14 30 R/T FCD IIb Ia
20 6 46 75 L/P FCD IIb Ib
Abbreviations: FCD focal cortical dysplasia, F frontal, ID patient identification number, L left, O occipital, P parietal, R right, T temporal.
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Temecula, CA, USA), pan-neuronal specific for non-
phosphorylated neurofilaments (SMI311R, 1:1000, Covance,
San Diego, CA, USA) and microtubule associated protein-
2a and b (MAP2, 1:200, Neomarkers, Freemont, CA, USA)
as neuronal markers; monoclonal antibody against glial fi-
brillary acidic protein (GFAP, 1:15000, Chemicon) as a
glial marker; monoclonal antibody against intermediate
filament protein vimentin (VIM, 1:3000, Dako, Carpinteria,
CA, USA) as a marker of BCs; and rabbit monoclonal anti-
body against phospho-S6 ribosomal protein (pS6 Ser235/
236, 1:500, Cell Signaling Technology, Beverly, MA, USA)
as a marker indicative of mTOR pathway hyperactivation.
The IHC procedures have been described in detail else-
where [27].
In situ hybridisation
In all cases, vibratome sections adjacent to the IHC sec-
tions were processed for in situ hybridisation (ISH) experi-
ments designed to detect Cux2, Rorβ, Er81, Nurr1 and
CTGF mRNA expression. Free-floating sections were in-
cubated with digoxigenin(DIG)-labelled riboprobes that
specifically hybridise with each of the five mRNA of inter-
est, and then with an alkaline phosphatase-conjugated
anti-DIG antibody (1:1000, Roche Diagnostics Mannheim,
Germany). The procedure and riboprobe characteristicshave been described in detail elsewhere [16,20,22,28].
There were no apparent signals in control sections with
the sense probes.
Quantitative analysis of ISH signals
To estimate the reduction of normal-looking neurons,
we counted the number of positive cells for the different
LSG in a single section for each sample using Image Pro
Plus 7.0 software (Media Cybernetics, Bethesta, MD,
USA). For each LSG, we outlined at 10× objective two
equal regions of interest (lesional area and, when present,
adjacent perilesional area) including the specific layer.
Using a 20× objective, all the immunopositive normal-
looking neurons within this area were manually counted.
The considered areas were: 1.44 mm2 for Cux2, 1.35 mm2
for Rorβ, 1.5 mm2 for Er81 and 1.1 mm2 for Nurr1. Dif-
ferences between lesional and perilesional areas were
assessed by means of a t test, with p-values of <0.05 be-
ing considered significant.
Double fluorescence ISH/IHC
It was not always possible to make a clear morphological
distinction between LSG-positive DNs and BCs when
BCs and giant round-shaped neurons coexisted in the
same areas. In these cases, we used double fluorescence
ISH/ICC combining Rorβ, Er81 and Nurr1 riboprobes
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vimentin antibodies (to identify BCs); the Cux2 riboprobe
was not used because of its low fluorescent hybridisation
signal. After the ISH procedures, the sections were incu-
bated overnight with a mixture of rabbit anti-DIG anti-
body (1:100000, Sigma, St. Louis, MO, USA) and mouse
anti-SMI (1:300) or anti-MAP2 (1:300) or anti-Vim anti-
bodies (1:300), and then incubated with biotinylated goat
anti-rabbit antibody (1:200, Vector, Burlingame, CA, USA)
and indocarbocyanine (Cy) 3-conjugated goat anti-mouse
antibody (1:500, Jackson Immunoresearch Laborator-
ies, West Grove, PA, USA) at room temperature for 60
minutes. Finally, the sections were incubated with
streptavidine-HRP (1:1000, PerkinElmer, Boston, MA,
USA) at room temperature for 30 minutes, and then
with biotinil tyramide fluorescinated in amplification
reagent (1:50, PerkinElmer) at room temperature for
three minutes. The fluorescent sections were examined
using a Nikon D-Eclipse C1 confocal laser scanning
microscope (Nikon, Tokyo, Japan) equipped with an argon-
ion laser system and mounted on a light inverted micro-
scope Eclipse TE2000 (Nikon).
Er81 and Nurr1 cortical layer thickness in perilesional
cortex
Sections of five samples of temporal cortex taken from
different patients and processed using the Er81 and
Nurr1 riboprobes were analysed in order to evaluate
possible changes in cortical distribution in the perile-
sional zone. The thickness of the layers was calculated
on the basis of the extent of the neurons labelled by each
riboprobe, and was expressed as a percentage of the total
depth of the cortical ribbon. Cortical thickness was mea-
sured only in the linear portion of the cortex, far from gyri
and sulci. One section per case was considered, and three
measures of each marker were made using scanned images
at 20× magnification (Scanscope; Aperio Technologies,
Vista, CA, USA). The data were compared with those
obtained in a previous study in witch six normal tem-
poral cortices were evaluated [22], and the differences




Table 1 shows the patients’ clinical data. Their mean age
at epilepsy onset was three years (range 0–10; SD 3) and
mean seizure frequency at the time surgery was 95 per
month (range 1–600; SD 145). Mean age at the time of
surgery was 20 years (range 1–47; SD 15), when the
mean duration of epilepsy was 16 years (range 1–43, SD
14). On the basis of the MRI diagnostic criteria recently
described by Colombo et al. [29], the imaging investiga-
tion allowed a diagnosis of Type II FCD in 19 patients(95%), whereas only temporo-polar blurring was observed
in one patient. Trasmantle sign was present in 12 patients.
The mean follow-up was five years (range 1–13; SD 3).
The surgical outcome was fairly good, with 16 patients in
Engel class I (80%; seven with Type IIa FCD and nine with
Type IIb); in particular, 13 patients are in Engel class Ia.
The remaining four patients are in class II, III, and IV be-
cause of the incomplete resection of the lesion. Although
the study population was small, the data concerning
seizure outcome are in line with previous reports
[29,30], thus suggesting that the good results were in-
dependent of the subtype and the site and side of the
excised lesion.Neuropathological characteristics of FCD
The resections of the 20 patients (eight with Type IIa
FCD and 12 with Type IIb) involved different cortical
areas (see Table 1). The analysed specimen from 16 pa-
tients (seven with Type IIa and nine with Type IIb) was
characterised by severe disruption of the laminar cortical
structure. DNs were distributed throughout the cortical
laminae except for layer I, sometime aggregated in neur-
onal clusters and, in six cases, were also present in the
underlying white matter (Figure 1a,d,e). In four patients
(one with Type IIa and three with Type IIb), the laminar
structure was less severely affected, with fewer DNs mainly
clustered in particular cortical layers (Figure 1b,f,g). How-
ever, it should be noted that other slabs from these cases
used for histopathology rather than LSG detection showed
profound disruption of the cortical architecture, suggest-
ing the periphery of the lesion. Both the severely and
less severely affected contained normal-looking neurons
intermingled with DNs (Figure 1j,k,m,n). BCs (the hall-
mark of Type IIb FCD identified by means of vimentin
immunopositivity) were always present in the white
matter (Figure 1l), and dispersed throughout the cortex
(in five cases) or clustered in layer I (three cases). Fifteen
of the 20 specimens showed a normal perilesional cortex
in which only rare and scattered DNs were detected
(Figure 1c,h,i).Layer-specific gene expression in FCD
The lamina-specific expression patterns of the consid-
ered genes have been previously demonstrated in normal
temporal and frontal cortex tissue: briefly, Cux2 mRNA
expression is observed in many cells in layers II and III;
Rorβ mRNA is intensely expressed in layer IV and a few
scattered cells in neighbouring layers; Er81 and Nurr1
mRNAs are respectively detected in neuronal subpopu-
lations in layers V and VI; and CTGF mRNA is observed
in a few cells in layer VI and the white matter [20,22].
An additional figure shows these features in detail (see
Additional file 1).
Figure 1 Histopathological features of surgical samples taken from patients with Type IIb FCD. a, d, e: Examples of a severe lesion
(parietal lobe): a, d (SMI immunoreactivity, ir) and e (NeuN ir) highlight typical features of Type II FCD, which is characterised by the total
disruption of cortical lamination and the presence of numerous DNs throughout the cortex intermingled with fewer normal-looking neurons. j, k:
Details of the regions marked with asterisks in d and e, respectively, show DNs that are clearly distinguishable by their very large size and abnormal
shape (arrows). In the same case, vimentin-positive BCs (l) are diffusely distributed in the subcortical white matter. b, f, g: Examples of a less severe
lesion (frontal lobe). b, f (SMI ir) and g (NeuN ir) showing cortical areas in which lamination is relatively preserved and DNs (arrows) are scattered
in restricted cortical layers (deep layers) intermingled with numerous normal-looking neurons. m, n: Details of the regions marked with asterisks
in f and g, respectively, show DNs (arrow) and normal-looking neurons. c, h, i: Examples of perilesional cortex (temporal lobe). c, h (SMI ir) and i
(NeuN ir) showing normal cortex adjacent to the principal lesion. Scale bars: 3.8 mm (a); 2.5 mm (b); 3.6 mm (c); 540 μm (d, e); 450 μm (f, g);
414 μm (h, i); 120 μm (j, k, m, n); 4.68 mm (l) and 50 μm for inset in l.
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Rorβ, Er81 and Nurr1 mRNAs were expressed in both ab-
normal and normal-looking neurons, which could be
clearly distinguished on the basis of their differently sized
bodies and nuclei (Figure 2a-d). CTGF mRNA expression
was scanty and observed only in a few normal cells in the
deep layers and in the white matter (data not shown).In the 16 specimens showing severe laminar disorgan-
isation and containing an adjacent perilesional area,
there was a clear-cut difference in the distribution and
signal intensity of gene expression moving from the core
of the lesion toward the perilesional area (Figure 3a,b).
Within the core of the lesion, normal-looking neurons
(identified on the basis of their normal size and shape)
Figure 2 Layer-specific gene (LSG) expression in normal-looking neurons and DNs. a-d: Adjacent sections, obtained from a parietal lobe,
showing regions expressing Cux2 (a), Rorβ (b), Er81 (c) and Nurr1 (d). In particular, areas from superficial cortex (sup.ctx), middle cortex (mid.ctx)
and the boundary between the deep cortex and the white matter (wm) are shown. For each LSG, normal-looking neurons (asterisks) and DNs
(stars) are easily distinguishable by their different size and shape (see high magnification images). Confocal double immunofluorescence images
combining immunoreactivity for neuronal markers (SMI311 and MAP2) with ISH for Er81 and Nurr1 showed the morphology of the normal-looking
neurons (e, f) and DNs (g, h,). Scale bars: 200 μm (a-d) and 60 μm for high magnification images; 55 μm (e-h).
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Cux2-positive cells in the upper cortex, Rorβ-positive
cells in the middle of the cortex, and Er81- and Nurr1-
positive cells in the deeper cortex (Figure 3d,g-j,l,n-q),
thus suggesting normal laminar organisation even in the
core of the lesion (compare Figure 3d with 3c). More-
over, these neurons were visibly reduced in number in
comparison with the adjacent perilesional area (particu-
larly those that were positive for Rorβ), thus reflecting
the reduced neuronal density inside the lesion (compare
Figure 3g-j with Figure 4b-e). This data were further
supported by quantitative analysis of normal-looking
neurons cell density (see Additional file 2). DNs (identi-
fied on the basis of their very large size and altered
morphology) showed the variable expression of all of the
LSGs except for CTGF, without any laminar specificity
(Figure 3g,j,l,m,r). The distribution of the DNs labelled by
different LSGs was uneven regardless of the subtype of
FCD (Type IIa vs IIb) and the lobar involvement of thedysplastic lesion. The details of LSG expression in each
case are shown in Figure 5.
In the four less severely affected specimens, the DNs were
prevalently localised in layers III or V/VI (Figure 6a, f). The
DNs labelled for Cux2, Er81 and Nurr1 (Figure 6d,e,i,j)
retained their correct laminar position (unlike in the se-
verely affected areas), and the normal-looking neurons
intensely labelled with LSGs were properly distributed
throughout the cortical thickness (Figure 6b-e, and g-j)
and their density was similar to that observed in the
perilesional cortex as confirmed by quantitative analysis
(see Additional file 2).
In the 15 specimens that included perilesional cortex
beside the core of the lesion, the laminar organisation was
normal (Figure 4a) with the regular distribution of the
LSGs in normal-looking neurons and no evidence of la-
belled DNs (Figure 4b-e). However, quantitative measure-
ment of cortical thickness showed Er81-positive cells were
more widespread throughout layer V than in the control
Figure 3 (See legend on next page.)
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(See figure on previous page.)
Figure 3 LSG expression in Type II FCD (severe area). Typical LSG expression in a case of Type IIa FCD (occipital lobe) histopathologically
characterised by a severe lesion with an adjacent perilesional area (a, SMI ir). b: Example of Er81 pattern showing intense expression in layer V of
the perilesional cortex (arrowheads), and less intense and dispersed expression in the core of the lesion. c-e: Single ISH images of each gene in
the severe lesion converted to pseudo-colour images (green for Cux2, fuchsia for Rorβ, yellow for Er81, and red for Nurr1) for overlay representation.
The cortical distributions of normal-looking neurons (NNs, d) and DNs (e) are shown separately, and juxtaposed with normal cortex for purposes of
comparison (c). Note the normal laminar distribution and reduced number of NNs in comparison with the dispersion of DNs. f-j: Adjacent sections
from the same case as that shown in a (SMI ir) and f (thionin staining), showing the expression of Cux2 (g), Rorβ (h), Er81 (i) and Nurr1 (j) mRNAs in
normal-looking neurons and DNs. k-r: Details of the regions marked with asterisks in f-j showing the morphological features of the NNs and DNs. Scale
bars: 5.2 mm (a, b); 240 μm (c-e); 195 μm (f-j); 50 μm (k-r).
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for control cortex, p = 0,025).
Layer-specific gene expression in BCs
BCs were identified in 12 cases on the basis of their mor-
phological features and vimentin immunolabelling, thus
allowing a diagnosis of Type IIb FCD. They were mainly
observed in the subcortical white matter (Figure 7a,b) but,
in some cases, they were also distributed throughout the
cortical thickness, and occasionally even invaded layer I.
As in the case of the DNs, the Cux2, Rorβ, Er81 and Nurr1
riboprobes were variably expressed in BCs (Figure 7 c-j)
with no specific labelling associated with their distributionFigure 4 LSG expression in perilesional cortex. Typical LSG expression i
a normal laminar organization and the absence of DNs (a, SMI ir). b-e: Adja
normal expression of Cux2 (b), Rorβ (c), Er81 (d) and Nurr1 (e). Scale bars: 2in the different cortical layers or lobar involvement.
These data were confirmed by the double fluorescent
experiments using vimentin and the different LSGs
(Figure 7k-p). Figure 5 shows the pattern of LSG expression
in the BCs of each case.
pS6 immunoreactivity in FCD
We observed immunoreactivity for pS6 in the DNs and
BCs. Labelled DNs were detected in both the severely
affected (Figure 8a,c) and less severely affected areas
(Figure 8b,d,e), whereas no specific expression of pS6 was
detected in the normal-looking neurons in either the core
of lesion or the adjacent perilesional area.n perilesional cortex (frontal lobe) histopathologically characterised by
cent sections from the same case as that shown in a showing the
95 μm (a-e).
Figure 5 Details of layer-specific gene expression in DNs and BCs. For each case, the presence of DNs positive for the different LSG is
indicated by a black or grey cell (the white cells indicate no labelling): the black cells indicate that DN distribution is severely affected, and the
grey cells indicate DNs distributed in their corresponding layers. In the case of BCs, the hatched cells indicate the presence of the different LSGs,
and the white cells indicate no labelling (nr = not clearly recognisable). Abbreviations: BCs: balloon cells; DNs: dysmorphic neurons; FCD: focal
cortical dysplasia; ID: patient identification number. *The site is the cortical area that underwent ISH analysis (O: occipital; T: temporal; F: frontal;
P: parietal).
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Focal cortical dysplasias are among the most frequent
brain malformations encountered in epileptic patients
undergoing surgical treatment. In particular, Type II
FCDs, which are often recognisable at the time of clin-
ical screening, are characterised by an early onset of epi-
lepsy, a high seizure frequency, and particular MRI and
EEG (or SEEG) pictures [29-32], and surgical treatment
often leads to seizure freedom even over long follow-up
periods [30]. The main neuropathological features of
Type II FCDs have been established since the original
description by Taylor et al. [1], and so their classifica-
tion has not varied in successive classification systems
[2,33]. However, although many immunohistochemical
studies have identified and characterised the various
neuronal populations involved in Type II FCD, its aeti-
ology and pathogenesis are unknown. The recent devel-
opmental and genetic classification of malformations of
cortical development (MCD) published by Barkowich
et al. [8] places Type II FCDs in the group of cortical
malformations secondary to abnormal neuronal and
glial proliferation, but the ontogenetic mechanisms
and embryonic time window in which the derangement
of cortical maturation and neuronal migration takes
place remain unclear.In order to gain more insights into the pathogenesis of
cortical malformations, new LSG-based approaches have
been proposed. Many different LSGs have been used in
studies of animal and human specimens, and their ex-
pression profiles through the cortical layers have been
defined; furthermore, it has been demonstrated that the
expression and laminar location of most LSGs is pre-
served during phylogenesis and pre- and postnatal devel-
opment [16-18,34]. On the basis of the assumption that,
once specified during embryonic development, neuronal
identity and laminar fate are apparently impervious to
change even if cell migration is abnormal, it has been
suggested that LSGs can be confidently used as markers
to study cortical malformations [13,35]. However, al-
though many studies have investigated different types of
MCD by means of LSGs, only a few have specifically
concentrated on Type II FCD [21,24,25,36].
The neuropathological hallmarks of Type II FCDs are
disrupted cortical lamination, reduced cortical neuronal
density, the presence of DNs and, in subtype IIb, the
presence of BCs. In relation to these, the main findings
of the present study are: i) although reduced in number,
normal-looking neurons retain their correct laminar
position even inside the core of the lesion, thus indicat-
ing a partial laminar organisation; ii) on the contrary,
Figure 6 LSG expression in Type II FCD (less severe area). Typical LSG expression in a case of Type IIb FCD (frontal lobe) histopathologically
characterized by a less severe lesion with DNs localised only in the deep portion of the cortex (a, SMI ir). b-e: Adjacent sections from the same
case as that shown in a showing the expression of Cux2 (b), Rorβ (c), Er81 (d) and Nurr1 (e). Note that Cux2 and Rorβ are expressed only in
normal-looking neurons (NNs) in the appropriate cortical laminae (b, c), whereas Er81 and Nurr1 (d, e) are expressed in both NNs and DNs in the
deep layers. f-j: Details of the regions marked with asterisks in b-e showing the morphological features of the NNs and DNs (arrows). Scale bars:
280 μm (a-e); 90 μm (f-j).
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white matter without any laminar specificity, and show a
highly variable LSG expression pattern; and iii) LSGs do
not reveal any differences between Type IIa and IIb
FCD.
The first and previously unknown finding is that the
normal-looking neurons, albeit markedly fewer in com-
parison with the fairly normal adjacent cortex, can be
found in the appropriate cortical laminae, which sug-
gests that a certain proportion are properly generated
and migrated. This implies that the genetic programme
for neuronal migration is not disrupted per se and that
the laminar disorganisation is mainly (if not exclusively)
due to altered DN migration. Lower neuronal density inthe region of the dysplasia than in the perilesional cortex
is a consistent finding in Type II FCD, and may be due
to different phenomena such as a local failure of cell
proliferation or enhanced neuronal vulnerability in this
area [3,4,37]; however, our data highlight for the first
time that the number of normal-looking neurons is par-
ticularly reduced.
The second finding is that DNs are not only haphaz-
ardly displaced but (particularly within the core of the
lesion) dispersed throughout the thickness of the cortex
regardless of the LSG they express: for example, Nurr1-
positive cells, which are normally found in the layer VI,
were also present in the superficial part of the cortex,
whereas Cux2-positive cells, which are normally found
Figure 7 Representative LSG expression in BCs. a, b. Example of Type IIb FCD (temporal lobe) characterised by a severe lesion with numerous
DNs dispersed throughout the cortex (a, SMI ir), and the presence of BCs in the white matter (b, vimentin ir). Adjacent sections from the same
case as that shown in a and b showing the expression of Cux2 (c), Rorβ (d), Er81 (g) and Nurr1 (h) in BCs in the white matter (boxed area in b).
Note the heterogeneous expression of the LSGs in the BCs. e, f, i, j: Details of the regions marked with asterisks in c, d, g and h showing the
morphological features of the BCs. Confocal double immunofluorescence images combining vimentin ir (red) with ISH for Er81 (k-m) and Nurr1
(n-p) confirmed the identification of the BCs. Scale bars:1, 41 mm (a); 1,27 (b); 357 μm (c, d, g, h); 92 μm (e, f, i, j); 70 μm k-p).
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ribbon and white matter. Unfortunately, technical problems
prevented us from using double-labelling in order to verify
whether DNs express more than one LSG.It is not possible to compare our findings with other
published data concerning Type II FCD because the stud-
ies used different LSGs and different methodologies (IHC
or ISH). Moreover, some published studies not specified
Figure 8 Representative pS6 expression in Type II FCD. Examples of pS6 expression in samples of severe (a) and less severe (b, arrows) Type
II FCD; in both cases, the immunoreactivity suggests the presence of mTOR pathway hyperactivation in DNs. c-e. Details of the regions marked
with asterisks in a, b. Scale bars: 268 μm (a,b); 60 μm (c,d,e).
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BCs) expressing different LSGs [24,25]. Furthermore, as
the LSGs we used are preserved during development, we
could not verify the hypothesis that some DNs may retain
the expression of genes that are exclusively present pre-
natally as previously suggested [21,24,25].
Our finding that different LSGs are expressed in DNs
improperly located in different layers of the cortex rib-
bon suggest that, whatever the defect, it occurred in the
early period of development. Recent developmental data
[38-41] indicate that radial glial cells (RGs) generate
neurons by means of multiple rounds of self-renewal
and asymmetric division, and that new-born neurons
often use the parent cell’s radial fibre to migrate to the
cortical plate [42]. Furthermore, it has been observed
that primate corticogenesis is characterised by the ap-
pearance of a large sub-ventricular zone (SVZ) that
seems to be important for the presence of resident pro-
genitor cells that contribute to neuronal production and
control neocortical size [43]. It has also been demon-
strated that two sub-classes of human RGs co-exist in
the ventricular zone (VZ) and the outer part of the SVZ
(OSVZ), each of which act as neural stem cells in theirrespective locations and provide a mechanism favouring
increased neuron production, which may be important
for building a larger brain [44].
Although cortical neuron production begins in the VZ
during gestational week 6 (GW6), the OSVZ does not
arise until GW11, but then dramatically expands over
the subsequent six GW to become the predominant ger-
minal region in the neocortex. This suggests that OSVZ
expansion and proliferation may increase the number of
late-born neurons destined to became the future upper
cortical layers, whereas the VZ generates the earliest-
born neurons destined to form the deep cortical layers.
On the basis of these developmental data, we can hy-
pothesise that, during the early stages of cortical devel-
opment (when the VZ is very actively proliferating and
gives rise to the post-mitotic neurons that migrate to
form the deep layers and the precursor cells for the
SVZ), one hit is sufficient to modify the future lineage of
some but not all progenitor cells in patients with Type II
FCD.
Another finding of our study is that, like the DNs, the
BCs expressed all of the LSGs regardless of their loca-
tion and even they were found in all of the layers. These
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http://www.actaneurocomms.org/content/2/1/45cells are immature, and their immunohistochemical pro-
files indicate the expression of vimentin, nestin and, in
some cases, markers of precursor cells [6]. They seem to
arise from radial cell precursors [11,21,45], but the fact
that some of them co-express neuronal markers suggests
aberrant cell-fate specification [5]. It is therefore con-
ceivable that this abnormal differentiation may have
been responsible for their labelling with our panel of
LSGs, which are typically expressed in excitatory neu-
rons. In any case, the fact that the distribution of LSGs
in BCs was similar to that observed in DNs further sup-
ports the hypothesis that the primary hit inducing the mal-
formation occurs during the early stages of development.
We did not identify any relationship between distinct
patterns of LSG expression and FCD subtype or lobar
involvement. The few published data in this regard are
controversial insofar as some authors (using different
LSGs) have found different distribution patterns and/or
different numbers of immunopositive cells in Type IIa
and IIb [24,25], whereas only Fauser et al. [36] have
found differences in lobar LSG expression.
The processes involved in cortical development (includ-
ing neurogenesis, cell migration and differentiation) are
highly synchronised and coordinated by extra- and intra-
cellular signals that converge on cytoskeletal remodelling
[46,47], and it has been demonstrated that mutations in
the genes encoding cytoskeletal proteins are involved in
many malformations of cortical development [48]. Inter-
estingly, one of the main histopathological features of
Type II FCD is the presence of DNs characterised by the
cytoplasmic engulfment of neurofilaments pushing the
nucleus to the cell periphery and disrupting the regular
distribution of chromatin. Similar DNs are found in
patients with TSC in whom TSC1 or TSC2 gene muta-
tions activate the mTOR cascade that affects many cell
biological processes, including the regulation of actin
dynamics [49].
In line with other recent findings [7,9,10], our data
show that the DNs were labelled with pS6 antibody, which
suggests that the mTOR pathway may also be involved in
Type II FCD. As no genetic impairment has been found in
this disease, it can be hypothesised that an “external”
phenomenon could hit some of the precursor cells acting
on the neuronal cytoskeletal framework very early during
cortical development (when the VZ is proliferating), and
that this leads to cytological alterations and the subse-
quently aberrant migratory stream. This would explain
the presence of normal-looking neurons that show no
changes in migration patterns.
In agreement with this hypothesis, the presence of a
localized central nervous system infection during fetal
brain development has been proposed as a new patho-
genic mechanism for Type II FCD. In fact, recent studies
have shown the presence of papillomavirus in BCs (but,surprisingly, not in DNs), and the presence of herpes
and cytomegalovirus infections in both BC and DNs [50,51].
Moreover, human papillomavirus, the most common
cause of cervical cancer in women, has been identified as
an activator of the mTOR signalling cascade and the cyto-
pathic effect of the infection on cervical epithelium results
in balloon-like cells similar to those observed in Type II
FCD. Although these data need further confirmation, they
are in line with the hypothesis that an external or environ-
mental hit affecting selected precursor cells during the
very early stages of cortical development may interfere
and disrupt normal cortical development as a result of
mTOR activation.
One intriguing aspect of our findings is the presence
of some DNs outside the core of the lesions (namely less
severe lesion) that retained their correct laminar position
in the cortical ribbon. Interestingly, like those associated
with severe lesions, these DNs were also labelled with
pS6 antibody. We do not have any definite explanation
for this feature, but hypothesise that the high frequency
of epileptic discharges characterising this form of dyspla-
sia may induce a secondary pathological plasticity lead-
ing to morphological rearrangements, as suggested in
various animal models [52].Conclusions
This study shows the existence of hidden cortical lamin-
ation involving normal-looking neurons, which retain
their ability to migrate correctly in the cortex, unlike DNs
which, in addition to their morphological abnormalities
and mTOR hyperactivation, show an altered migratory
pattern. BCs also expressed all of the LSGs regardless of
their location. Taken together these data suggest that an
external or environmental hit affecting selected precursor
cells during the very early stages of cortical development
may disrupt normal cortical development.Additional files
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